Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 277.00
Bid: 277.00
Ask: 281.00
Change: -7.00 (-2.46%)
Spread: 4.00 (1.444%)
Open: 290.00
High: 290.00
Low: 277.00
Prev. Close: 284.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

Tue, 03rd May 2022 11:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Vast Resources PLC, up 50% at 0.51 pence, 12-month range 0.08p-10.00p. The Romania and Zimbabwe-focused miner says revenue more than doubled to USD2.3 million in the first quarter from USD970,465 in the fourth quarter. Reports increase in tons milled and in dry-metric-ton production at the Baita Plai polymetallic mine in Romania.

----------

Eneraqua Technologies PLC, up 10% at 280.00p, up 1.1% from November listing price of 277.00p. The energy and water efficiency services provider wins contract from the Indian state government of Uttarakhand to reduce carbon emissions and improve water efficiency. The northern state has a population of over 10 million people. Contract is worth GBP900,000 from the state's Department of Horticulture will see Eneraqua supply systems to 340 horticultural farms across the state.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 15% at 208.00p, 12-month range 202.50p-656.00p. The US Food & Drug Administration has rejected the drugmaker's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
19 Aug 2015 11:24

Hutchison China MediTech Says Janssen Terminates HMPL-507 Agreement

Read more
28 Jul 2015 11:26

Hutchison China first-half profit drops as research spending rises

(ShareCast News) - Healthcare group Hutchison China MediTech posted a drop in first-half pre-tax profit as it invested more heavily in research and development. For the six months ended 30 June, pre-tax profit came in at $3.9m from $7.3m as a higher spend in R&D and cost of sales offset an increase

Read more
28 Jul 2015 07:20

Hutchison China MediTech First Half Profit Down As It Ups Investment

Read more
23 Jul 2015 08:13

Hutchison China MediTech Says Mitsui Takes 6% Direct Stake (ALLISS)

Read more
17 Jul 2015 08:32

BROKER RATINGS SUMMARY: Investec Cuts Barclays To Sell From Hold

Read more
17 Jul 2015 07:27

LONDON BRIEFING: M&S Shares Sold As General Merchandise Chief Departs

Read more
17 Jul 2015 06:35

Hutchison China MediTech Gets Patent For Key Cardiovascular Pill

Read more
1 Jun 2015 06:59

Hutchison China MediTech Says Savolitinib Trial Results Encouraging

Read more
13 May 2015 06:53

Hutchison China MediTech To Get USD18 Million Payment From Eli Lilly

Read more
17 Apr 2015 11:48

DIRECTOR DEALINGS SUMMARY: Telecom Plus Directors Buy After Warning

Read more
16 Apr 2015 12:35

DIRECTOR DEALINGS: Hutchison China Chairman Buys More Shares

Read more
13 Apr 2015 08:46

DIRECTOR DEALINGS: Hutchison China Chairman Buys 25,000 Shares

Read more
10 Apr 2015 13:02

DIRECTOR DEALINGS SUMMARY: CVS Group CEO Halves Stake

Read more
8 Apr 2015 15:36

Hutchison China Meditech chairman buys £0.8m worth of shares

Hutchison China MediTech revealed on Wednesday its chairman and secretary bought some shares in the company. Executive director and chairman Simon To on Tuesday purchased 48,000 shares for 1385p each, spending £664,800 in the transaction. Furthermore, non-executive director and secretary Edith Shih

Read more
8 Apr 2015 08:42

DIRECTOR DEALINGS: Hutchison China MediTech Directors Buy Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.